INmune Bio (NASDAQ:INMB – Get Free Report) and AIM ImmunoTech (NYSE:AIM – Get Free Report) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, profitability, dividends, risk, analyst recommendations, earnings and institutional ownership.
Profitability
This table compares INmune Bio and AIM ImmunoTech’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| INmune Bio | -26,333.59% | -117.48% | -78.96% |
| AIM ImmunoTech | -12,594.21% | -421.73% | -147.54% |
Valuation and Earnings
This table compares INmune Bio and AIM ImmunoTech”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| INmune Bio | $42,000.00 | 2,898.20 | -$30.01 million | ($2.18) | -2.52 |
| AIM ImmunoTech | $190,000.00 | 72.17 | -$28.96 million | ($0.47) | -0.46 |
Institutional & Insider Ownership
12.7% of INmune Bio shares are owned by institutional investors. Comparatively, 12.0% of AIM ImmunoTech shares are owned by institutional investors. 35.2% of INmune Bio shares are owned by insiders. Comparatively, 0.0% of AIM ImmunoTech shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Analyst Recommendations
This is a summary of recent recommendations and price targets for INmune Bio and AIM ImmunoTech, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| INmune Bio | 0 | 0 | 3 | 0 | 3.00 |
| AIM ImmunoTech | 0 | 0 | 2 | 0 | 3.00 |
INmune Bio currently has a consensus target price of $20.00, indicating a potential upside of 264.30%. AIM ImmunoTech has a consensus target price of $2.75, indicating a potential upside of 1,179.07%. Given AIM ImmunoTech’s higher probable upside, analysts plainly believe AIM ImmunoTech is more favorable than INmune Bio.
Volatility & Risk
INmune Bio has a beta of 1.78, meaning that its share price is 78% more volatile than the S&P 500. Comparatively, AIM ImmunoTech has a beta of -0.36, meaning that its share price is 136% less volatile than the S&P 500.
Summary
INmune Bio beats AIM ImmunoTech on 7 of the 13 factors compared between the two stocks.
About INmune Bio
INmune Bio, Inc., a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. The company's development programs include INKmune, which is in Phase 1 for the treatment of patients with high-risk myelodysplastic syndrome; and INB03, a mucinous polyglucan on the surface of some epithelial cancer cells that appears to predict resistant to immunotherapy, including women with MUC4 expressing HER2+ breast cancer and other MUC4 resistant cancers. It also provides XPro1595 for the treatment of Alzheimer's disease and treatment resistant depression. It has license agreements with Xencor, Inc.; Immune Ventures, LLC; and University of Pittsburg. INmune Bio, Inc. was incorporated in 2015 and is headquartered in Boca Raton, Florida.
About AIM ImmunoTech
AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's lead product candidate is Ampligen, a drug of macromolecular ribonucleic acid molecules for the treatment of chronic fatigue syndrome (CFS). It is also developing Ampligen for the treatment of pancreatic, renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, and prostate cancers, as well as for myalgic encephalomyelitis, Hepatitis B, HIV, COVID-19, and post-COVID conditions. In addition, the company provides Alferon N Injection, an injectable formulation of natural alpha interferon to treat human papilloma viruses, and genital warts, a sexually transmitted disease. AIM ImmunoTech Inc. has agreements with Amarex Clinical Research LLC; University of Cagliari Dipartimento di Scienze della Vita e dell'Ambiente; Jubilant HollisterStier; Sterling Pharma Solutions; Erasmus University Medical Center Rotterdam; Azenova, LLC; and Alcami Corporation. The company was formerly known as Hemispherx Biopharma, Inc. and changed its name to AIM ImmunoTech Inc. in August 2019. AIM ImmunoTech Inc. was incorporated in 1966 and is headquartered in Ocala, Florida.
Receive News & Ratings for INmune Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for INmune Bio and related companies with MarketBeat.com's FREE daily email newsletter.
